UBS Group
GPCR icon

UBS Group’s Structure Therapeutics GPCR Stock Holding History

UBS Group’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-400
Closed -$27.8K – 10762
2025
Q4 		$27.8K Sell
400
-20,700
-98% -$845K ﹤0.01% 7576
2025
Q3 		$591K Sell
21,100
-10,100
-32% -$201K ﹤0.01% 5967
2025
Q2 		$647K Buy
31,200
+22,300
+251% +$490K ﹤0.01% 5802
2025
Q1 		$154K Sell
8,900
-27,400
-75% -$671K ﹤0.01% 6722
2024
Q4 		$984K Buy
+36,300
New +$1.29M ﹤0.01% 5309

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

UBS Group's GPCR Position: Q2 2026 in Review

UBS Group increased its Structure Therapeutics (GPCR) stake by 78% in Q2 2026, buying an estimated $7.35M and bringing the position to 378,986 shares worth $20.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2658.

UBS Group first reported a position in GPCR in Q2 2023 and has held it in 12 quarters since. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • UBS Group held 378,986 shares of Structure Therapeutics worth $20.3M as of Q2 2026.
  • UBS Group bought 166,067 Structure Therapeutics shares in Q2 2026, an estimated $7.35M.
  • Structure Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2658 holding.
  • UBS Group first reported a position in Structure Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.